Pharma's post-Covid growth faces challenges as margin compression and strategic shifts emerge in 2026, urging a bottom-up ...

Although trust in pharma spiked during the pandemic, it seems companies' reputations are back to pre-COVID-19 levels—and there’s bad news for the biggest COVID vaccine makers. That’s according to a ...

World-class Kabuki theatre took the stage at the U.S. International Trade Commission (USITC) last week. Big Pharma interests raged en masse: Death and misery would befall us all if the U.S. government ...

Last week the US Center for Biologics Evaluation and Research (CBER) released its plans for evaluating vaccines prompted by ...

Fosun Pharma’s revenue grew slightly in the first quarter on its diverse product portfolio, while its net profit soared by 116%. CanSino’s revenue plunged 80% in the same three-month period, and it ...

The financial performance of major pharmaceutical companies highlights the divergent trajectories of success of GLP-1 manufacturers and the weakness caused by diminishing Covid-19 sales. Eli Lilly and ...

LONDON, July 19 (Reuters) - An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for COVID-19 ...

In the wake of the memo, several vaccine experts responded that the CBER director's claim about the deaths requires more ...

By 2025, more than 13 billion doses of the vaccine are estimated to have been administered globally, saving untold millions of lives and suffering.

Covid-19 vaccines did not lead to higher death rates in France, according to a new study using data from 30 million adults.